ZEISS CLARUS 700 Receives NMPA Approval in China
ZEISS Medical Technology expands retinal insights for ophthalmologists with ultra-widefield, high-resolution imaging capabilities
JENA, Germany and SHANGHAI, June 5, 2025 /CNW/ -- ZEISS Medical Technology announced today that the CLARUS® 700 from ZEISS has received National Medical Products Administration (NMPA) approval in China, offering advanced retinal diagnostic capabilities with ultra-widefield, high-resolution images in True Color and unsurpassed quality. The fundus imaging device with Fluorescein Angiography helps eye care specialists in China unlock the full potential of their clinic's retina workflow to support improved patient vision preservation.
"ZEISS CLARUS 700 represents a major step forward in retinal imaging," emphasizes Anuj Kalra, Head of Chronic Disease Management at ZEISS Medical Technology. "By seamlessly integrating ultra-widefield Fluorescein Angiography (FA) imaging with true-color reproduction, this system delivers unprecedented clarity for comprehensive visualization from the macular region to the extreme retinal periphery, enhancing efficiency and supporting precise decision-making within the ZEISS Retina Workflow."
"Integrating ultra-widefield imaging, unsurpassed clarity, and AI-enhanced capture, the CLARUS 700 redefines fundus angiography benchmarks. It will provide unparalleled diagnostic precision for Chinese doctors and unprecedented comfort for their patients," says Maxwell Liu, Head of Sales & Services at ZEISS Medical Technology China.
Ultra-widefield fluorescein angiography serves as a highly valuable examination tool for assessing nonperfused retinal areas. The ZEISS CLARUS 700 HD ultra-widefield fundus imaging camera is an advanced retinal imaging system that provides True Color, high-resolution images. It captures 133°1 in a single image and up to 267° with multiple captures, offering detailed views of the retina. Equipped with both fluorescein angiography and live infrared imaging capabilities, the CLARUS 700 aids in diagnosing and monitoring retinal diseases2. Furthermore, the fundus imaging camera offers innovative technology features including PrecisionFocus for quickly seeing details in the regions of interest, QuickCompare to compare pathology changes observed in past patient visits, and AutoBright so ophthalmologists can spend more time analyzing images and less time adjusting them.
More information about the CLARUS® 700 from ZEISS can be found here.
1 CLARUS 700#white-paper2 Xiao, Y., Dan, H., Du, X. et al. Assessment of early diabetic retinopathy severity using ultra-widefield Clarus versus conventional five-field and ultra-widefield Optos fundus imaging. Sci Rep 13, 17131 (2023). https://doi.org/10.1038/s41598-023-43947-5
Not all products, services or offers are approved or offered in every market and approved labeling and instructions may vary from one country to another. For country-specific product information, see the appropriate country website. Product specifications are subject to change in design and scope of delivery as a result of ongoing technical development. The statements of the healthcare professionals reflect only their personal opinions and experiences and do not necessarily reflect the opinion of any institution that they are affiliated with. The healthcare professionals alone are responsible for the content of their experience reported and any potential resulting infringements. Carl Zeiss Meditec AG and its affiliates to not have clinical evidence supporting the opinions and statements of the health care professionals nor accept any responsibility or liability of the healthcare professionals' content. The healthcare professionals have a contractual or other financial relationship with Carl Zeiss Meditec AG and its affiliates and have received financial support.
Contact for investorsSebastian FrericksDirector Investor RelationsCarl Zeiss Meditec AGPhone: +49 3641 220 116Mail: investors.med@zeiss.com
Contact for the pressFrank SmithHead of Global Communications OphthalmologyCarl Zeiss Meditec Inc.Phone: +49 3641 220 331Mail: press.med@zeiss.com
www.zeiss.com/newsroom
Brief Profile
Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With 5,730 employees worldwide, the Group generated revenue of €2,066.1m in fiscal year 2023/24 (to 30 September).
The Group's head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 39 percent of Carl Zeiss Meditec AG's shares are in free float. Approx. 59 percent are held by Carl Zeiss AG, one of the world's leading groups in the optical and optoelectronic industries.
For further information visit: www.zeiss.com/med
View original content to download multimedia:https://www.prnewswire.com/news-releases/zeiss-clarus-700-receives-nmpa-approval-in-china-302473929.html
SOURCE Carl Zeiss Meditec AG
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/June2025/05/c8118.html
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
37 minutes ago
- Yahoo
Musk's Political Exit Results In More Volatility for Tesla Stock — Experts Answer Whether You Should Buy the Dip
Elon Musk has taken a step back from politics, and some investors are excited about the tech billionaire's renewed focus on Tesla. Musk's entrepreneurial successes and ability to think ahead are one of the main reasons that Tesla stock commands a high premium. Learn More: Read Next: Some people see Musk's exit from politics as a good thing for the stock, while others still don't view it as a buying opportunity. The recent spat between Musk and Trump has created even more uncertainty for the stock, but fear can create opportunities. Several experts shared their thoughts about the electric vehicle (EV) maker. Elon Musk's involvement in the Department of Government Efficiency has stirred up controversy. Liberals make up a large percentage of EV buyers, and many people in this group adamantly turned against the tech billionaire. Robert P. Johnson, PhD, certified financial advisor (CFA), CAIA, professor of finance at Creighton University's Heider College of Business, views Musk's DOGE departure as good for business, but he has to clear a few hurdles. 'More attractive, but there are a couple of problems. First, Musk himself has seemingly always divided his time between several endeavors — Space X, X (formerly Twitter), Neuralink, etc. Second, his DOGE involvement also negatively impacted Tesla in the sense that he alienated a large part of his current and potential owner base by aligning himself with Trump,' Johnson explained. Find Out: While liberals have been turned off by Musk, he also risks losing conservatives due to a recent string of X posts. 'Now, his criticism of the 'Big, Beautiful Bill' may alienate potential buyers of Teslas who are supporters of Trump. In other words, Musk has seemingly alienated people on both sides of the political aisle,' Johnson added. 'Wading into politics is a losing proposition for the CEO of a publicly traded company, particularly one with as high a visibility as Musk.' Musk committing more of his time to Tesla isn't only a tailwind for its EVs. Tesla has been working on several projects, such as robotaxis and humanoid robots, that have the potential to deliver massive gains for patient investors. Alex Black, chief marketing officer at EpicVIN, encourages investors to consider all of Tesla's underlying businesses before making a decision. 'This is not an auto company — it's energy, software, AI, all in one. High potential, high volatility. Monitor margins, delivery numbers, and how they're competing against Chinese competition. And remember: Hype drives this stock more than rationale at times,' Black said. He also suggested considering where you are with your finances before making an investment. Your age plays a big role in the types of assets you should consider. 'Are you young and have time to take the ups and downs? Future tech in the form of EVs, AI and autonomy may be worth it,' according to Black. 'But if you're close to retirement, playing it safe with solid, proven companies is the better bet. Diversify a bit if possible.' Another problem for Tesla is the rising competition. BYD is a leading EV maker that is gobbling up market share in China, Europe and Mexico. Competition can present several problems for the valuation. John Ellmore, editor and spokesperson for Electric Car Guide, shares what investors should monitor. 'Investors need to look past the brand and dig into the numbers. Tesla's margins are tightening, sales are flatlining in key markets and the competition is delivering cheaper EVs at scale,' he pointed out. 'I think the market is catching up, so I would urge caution for would-be investors.' Musk's return to Tesla can minimize concerns about competition. The tech billionaire may have additional time to focus on Tesla and regain lost ground. Editor's note on political coverage: GOBankingRates is nonpartisan and strives to cover all aspects of the economy objectively and present balanced reports on politically focused finance stories. You can find more coverage of this topic on More From GOBankingRates How Far $750K Plus Social Security Goes in Retirement in Every US Region This article originally appeared on Musk's Political Exit Results In More Volatility for Tesla Stock — Experts Answer Whether You Should Buy the Dip Erreur lors de la récupération des données Connectez-vous pour accéder à votre portefeuille Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données
Yahoo
an hour ago
- Yahoo
JCR Pharmaceuticals Marks 50 Years of Innovation with Launch of One-of-a-Kind Global Website
- A refreshed global brand signals JCR's expanded international presence and unwavering focus on rare and genetic diseases worldwide - HYOGO, Japan, June 06, 2025--(BUSINESS WIRE)--JCR Pharmaceuticals Co., Ltd. (TSE 4552; "JCR"), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announced the launch of its new global website. As the company turns 50, it is marking its growing footprint in Japan, the U.S., Europe, and Latin America with a unique website tailored for global audiences that reflects its passion for both science and humanity and brings the JCR brand to life for patients, physicians, and partners worldwide. "At JCR, we are committed to advancing science and delivering on the treatments for patients with unmet needs around the world," said Shin Ashida, Chairman, President and CEO of JCR Pharmaceuticals. "In September, we celebrate the 50th anniversary of the company I founded in 1975. The launch of our new global website reflects our evolution from an innovative startup in Japan to a global biopharmaceutical company. We remain dedicated to developing therapies for people with rare and genetic diseases and partnering with those who share our vision of transforming care for patients and families living with once untreatable diseases." The site features streamlined user interface and curated content for patients, physicians, partners, and investors – reinforcing JCR's commitment to bridge the gap between complex science and unmet needs of patients and families. For the past 50 years, JCR has built a reputation for the development of innovative new therapeutic approaches, including its more recent J-Brain Cargo® technology, a proprietary blood-brain barrier-penetrating technology that can deliver biotherapeutics into the central nervous system (CNS). This platform underpins several investigational pre-clinical and clinical staged therapies in JCR's pipeline, beginning with lysosomal storage disorders (LSDs), and it reflects the company's ongoing commitment to advancing treatments for CNS-related diseases across neurodegeneration, neuro-inflammation, and neuro-oncology conditions. JCR continues to strengthen its global research, development, and manufacturing capabilities, with a focus on addressing unmet medical needs and expanding therapeutic possibilities. Learn more about JCR, its technologies, and clinical development programs on its global website: About the J-Brain Cargo® Platform Technology JCR Pharmaceuticals has developed a proprietary blood-brain barrier-penetrating technology, J-Brain Cargo®, to bring biotherapeutics into the central nervous system. The first drug developed based on this technology and approved in Japan for the treatment a lysosomal storage disorder is IZCARGO® (INN: pabinafusp alfa). About JCR Pharmaceuticals Co., Ltd. JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceutical company that develops treatments that go beyond rare diseases to solve the world's most complex healthcare challenges. We continue to build upon our 50-year legacy in Japan while expanding our global footprint into the U.S., Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II, MPS IIIA and B (Sanfilippo syndrome type A and B), and more. Our core values – Putting people first, Forging our own path, Always advancing, and Committed to excellence – mean that the work we do benefits all our stakeholders, including employees, partners, and patients. We strive to expand the possibilities for patients while accelerating medical advancement at a global level. For more information, please visit the global website: View source version on Contacts Investors & Media:JCR Pharmaceuticals Co., Communicationsir-info@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
an hour ago
- Yahoo
AI-Powered Vehicle Inspection Company iNeedaPPi Expands Across Canada, Offering Fast, Affordable, and Transparent Used Car Evaluations
TORONTO, June 6, 2025 /CNW/ -- iNeedaPPi Mobile Car Inspectors, a Canada-based company known for its technology-driven approach to used vehicle inspections, has expanded across the Canadian market with operations available in and around Toronto, Vancouver, Calgary, and Edmonton. The service addresses long-standing concerns among used car buyers—namely, how to confidently evaluate a vehicle's condition without relying on the seller or traditional, often inconsistent inspection processes. The company leverages AI technology, machine learning, and proprietary tools to ensure every inspection is thorough, consistent, and unbiased, regardless of who performs it or where. This data-centric model aims to improve trust and transparency in an area of the automotive industry where both are often lacking. Mobile, Same-Day Car Inspections for Only $169.99 iNeedaPPi offers on-location pre-purchase inspections that are typically completed within the same day, priced at $169.99. Once a buyer places an order through the website, iNeedaPPi coordinates directly with the seller to schedule the inspection. The buyer then receives a comprehensive report via email—no coordination or in-person meetings required. Visual, Evidence-Based Reporting Inspection reports are built for clarity and visual understanding. Each includes: Over 50 high-resolution photos Video documentation showing the vehicle in action A detailed condition score out of 100 Objective summaries and visual evidence of any issues These features are designed to reduce ambiguity and give buyers the ability to make fully informed decisions without relying solely on trust or vague descriptions. Added Tools for Buyer Confidence Customers can add a $25 Market Price Appraisal at checkout to learn what a vehicle is really worth in today's market. For additional peace of mind, iNeedaPPi now also offers optional post-purchase warranty coverage, with plans starting at just $49 for 90 days. A Smarter Way to Buy Used By combining speed, affordability, and technological innovation, iNeedaPPi aims to transform how Canadians shop for used vehicles. With fast service, unbiased results, and no pressure to buy, it offers a modern alternative to the traditional, often stressful, car-buying experience. As more buyers turn to private sellers and online marketplaces, iNeedaPPi arrives at a critical time—making it easier than ever to buy used with clarity, protection, and confidence. SOURCE iNeedaPPi Mobile Car Inspectors View original content to download multimedia:
